Literature DB >> 19440078

Evaluation of a urine on-site drugs of abuse screening test in patients admitted to a psychiatric emergency unit.

Gunnhild Bagøien1, Gunnar Morken, Kolbjørn Zahlsen, Trond Aamo, Olav Spigset.   

Abstract

The objective of this study was to characterize the usefulness and reliability of a commonly used urinary on-site drugs of abuse screening test device when used routinely at admittances to a psychiatric emergency unit. Urine samples from 262 emergency psychiatric admittances representing 217 patients were analyzed by a commercially available on-site test for the detection of amphetamines, benzodiazepines, cannabis, cocaine, and opiates in urine. The samples were first screened by nurses at the psychiatric department, thereafter by 2 technicians at the laboratory, and finally, analyzed by liquid chromatography/mass spectrometry. Results of 45.8% of the screening tests were true negative for all 5 drugs/drug groups tested, whereas those of 29.4% were true positive for 1 or several drugs/drug groups and true negative for the others. Thus, in total, 75.2% were correct for all 5 drugs/drug groups. In general, the sensitivities (42.9%-90.0% for the various drug groups) were lower than the specificities (92.7%-100.0%). The accuracies were 86.3% for benzodiazepines, 92.4% for cannabis, 94.7% for opiates, and 97.0% for amphetamines. No cocaine was found in any of the samples. For cannabis, the accuracy was higher among the laboratory technicians than among the nurses. The results from on-site screening testing should not be considered as the final conclusion on the intake of drugs of abuse but must be interpreted with caution.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19440078     DOI: 10.1097/JCP.0b013e3181a45e78

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  7 in total

Review 1.  'Medical Clearance' of Patients With Acute Mental Health Needs in the Emergency Department: A Literature Review and Practice Recommendations.

Authors:  Tony W Thrasher; Martha Rolli; Robert S Redwood; Michael J Peterson; John Schneider; Lisa Maurer; Michael D Repplinger
Journal:  WMJ       Date:  2019-12

2.  Pharmacological interventions in the treatment of the acute effects of cannabis: a systematic review of literature.

Authors:  José As Crippa; Guilherme N Derenusson; Marcos Hn Chagas; Zerrin Atakan; Rocio Martín-Santos; Antonio W Zuardi; Jaime Ec Hallak
Journal:  Harm Reduct J       Date:  2012-01-25

3.  Challenges in detecting and diagnosing substance use in women in the acute psychiatric department: a naturalistic cohort study.

Authors:  Torill Vassli Sallaup; Arne Einar Vaaler; Valentina Cabral Iversen; Ismail Cuneyt Guzey
Journal:  BMC Psychiatry       Date:  2016-11-17       Impact factor: 3.630

4.  Inhaled Loxapine for Agitation in Intoxicated Patients: A Case Series.

Authors:  Carlos Roncero; Elena Ros-Cucurull; Raúl Felipe Palma-Álvarez; Alfonso Carlos Abad; Christian Fadeuilhe; Miquel Casas; Lara Grau-López
Journal:  Clin Neuropharmacol       Date:  2017 Nov/Dec       Impact factor: 1.592

Review 5.  American Association for Emergency Psychiatry Task Force on Medical Clearance of Adult Psychiatric Patients. Part II: Controversies over Medical Assessment, and Consensus Recommendations.

Authors:  Michael P Wilson; Kimberly Nordstrom; Eric L Anderson; Anthony T Ng; Leslie S Zun; Jennifer M Peltzer-Jones; Michael H Allen
Journal:  West J Emerg Med       Date:  2017-05-01

6.  The effects of motivational interviewing on patients with comorbid substance use admitted to a psychiatric emergency unit - a randomised controlled trial with two year follow-up.

Authors:  Gunnhild Bagøien; Johan Håkon Bjørngaard; Christine Østensen; Solveig Klæbo Reitan; Pål Romundstad; Gunnar Morken
Journal:  BMC Psychiatry       Date:  2013-03-21       Impact factor: 3.630

7.  Study protocol of the ESUB-MG cluster randomized trial: a pragmatic trial assessing the implementation of urine drug screening in general practice for buprenorphine maintained patients.

Authors: 
Journal:  BMC Fam Pract       Date:  2016-03-01       Impact factor: 2.497

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.